Flu Season Alert!Alerta de temporada de influenza:
Don’t let germs win this season – protect yourself and your family!
The flu vaccine is your best defense against flu and related complications – PLUS, it is a covered benefit for Texas Children’s Health Plan members! Learn more!
¡No permitas que los gérmenes ganen esta temporada! ¡Protégete a ti y a tu familia!
La vacuna contra la influenza es tu mejor defensa contra la influenza y sus complicaciones. Además, ¡es un beneficio cubierto para los miembros de Texas Children's Health Plan! Aprende más
Texas Medicaid PDL Changes for Adalimumab (Humira) Products
Date: September 17, 2025
Attention: All Providers
Subject: Texas Medicaid PDL Changes for Adalimumab (Humira) Products
Call to action: Texas Children’s Health Plan (TCHP) would like inform providers that effective July 28, 2025 the Texas Health and Human Services Commission (HHSC) has updated the Texas Medicaid Preferred Drug List (PDL) for adalimumab (Humira) products.
In addition to the reference product Humira, three FDA approved biosimilars are now available as preferred medications on the Texas Medicaid PDL: adalimumab-ADAZ, Hadlima (adalimumab BWWD and Simlandi (adalimumab-RYVK). All other biosimilar products for Humira are non-preferred and will require PDL prior authorization.
Preferred PDL products are available at a considerable cost savings compared to non-preferred PDL products, reflecting HHSC’s ongoing review of clinical evidence supporting biosimilar equivalence and cost-effectiveness.
Texas Medicaid PDL Preferred
Texas Medicaid PDL Non-Preferred
adalimumab-ADAZ
HADLIMA (adalimumab BWWD)
SIMLANDI (adalimumab-RYVK)
HUMIRA (adalimumab)
adalimumab-ADBM
AMJEVITA (adalimumab-ATTO)
CYLTEZO (adalimumab-ADBM)
HYRIMOZ (adalimumab-ADAZ)
As healthcare expenditures rise, biosimilar drugs represent a clear opportunity to reduce healthcare costs while maintaining patient access to treatment options for patients. To support this goal, we encourage providers to transition patients currently prescribed non-preferred PDL products to one of the following preferred biosimilar alternatives, when clinically appropriate and in the best interest of the patient: adalimumab–ADAZ, Hadlima (adalimumab-BWWD) or Simlandi (adalimumab-RYVK). This can be accomplished by either writing a new prescription with a DAW-1 (Dispense-As-Written) notation. Providers are not required to complete a new prior authorization unless the previous prior authorization for a non-preferred PDL product has expired.
Next steps: Providers should share this communication with their staff.
